Literacy is being redefined in our era of digital technology. The language of coding is becoming an essential element of literacy in the United States—as Latin and Greek once were for ambitious American colonists when the Declaration of Independence was signed... Read more »
Workers who already have a college degree now often top off their credentials by doing a stint at a code school—July and August are the peak enrollment periods, says San Francisco-based online code school Bloc. Others seek graduate degrees in... Read more »
Here we are at the midpoint of 2016 already. Time to look back on the past six months—and some of the top stories of the year so far.
The following represent a cross-section of what Xconomy offers on a daily basis:... Read more »
The word of the week was “moonshot,” as U.S. Vice President Joe Biden’s cancer initiative convened a summit in Washington, DC. At the gathering, Biden took verbal shots at scofflaw cancer researchers and at drug prices, while the FDA said... Read more »
[Corrected 6/30/16, 2:49 p.m. See below.] Google Capital’s $46.35 million investment in publicly traded Care.com, announced Wednesday, marked a departure from the firm’s usual bets on late-stage private companies and illustrated how the traditional lines in the venture capital... Read more »
As part of a national cancer “moonshot” initiative led by Vice President Joe Biden, the FDA said Wednesday it would retool the way it evaluates cancer treatments and tests.
But to what end?
The goals of the FDA’s new Oncology Center... Read more »
Inside our bodies, our cells move around, communicate, form new tissue, and heal wounds with the help of proteins called integrins. But when disease occurs, integrins get the wrong cues and do damage—they might help tumors grow, or promote inflammation or... Read more »
Roboticists covered a sweeping range of topics at Xconomy’s annual Robo Madness West conference last week, from the ethics of artificial intelligence to the powerful impact of robots that have faces.
Two themes ran through all the panel discussions, whether they... Read more »
Moderna Therapeutics still hasn’t produced data in humans supporting its technology, which is meant to turn our bodies into little drugmaking factories. But the Cambridge, MA-based company nonetheless keeps grabbing the attention, and cash, of other drugmakers.
Moderna said today that... Read more »
The Boston-area cybersecurity scene is ripe with acquisition targets. IBM bought incident-response firm Resilient Systems earlier this year. Now, Cisco Systems says it is acquiring CloudLock, a Waltham, MA-based cloud security company, for $293 million in cash and stock, plus... Read more »
The outlook for Infinity Pharmaceuticals didn’t look good after its blood cancer drug, duvelisib, came up short in a critical clinical trial a few weeks ago, and the situation has gotten worse today. AbbVie has sent the rights to duvelisib back... Read more »
A new wave of drugs has changed the way hepatitis C is treated. Regulus Therapeutics has not been part of that wave, but the company’s plans to join it took a big hit this afternoon.
La Jolla, CA-based Regulus (NASDAQ: RGLS... Read more »
Just another billion-dollar exit for a Massachusetts company most people have never heard of. This one has an interesting backstory, in a field rife with consolidation and would-be deals.
HeartWare International said Monday it is being acquired by medical device giant... Read more »